Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

A new study published in the Journal of Clinical Tuberculosis and Other Mycobacterial Diseases showed that two ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.

On September 10, experts across disciplines, from infectious disease clinicians to regulators to representatives from the pharmaceutical industry, convened at the inaugural ImmunOptimize workshop in ...

Nevirapine and efavirenz are recommended as key drugs in the latest first-line regimens. NNRTIs bind to a hydrophobic pocket near the catalytic site of HIV-1 RT and inactivate enzymatic activity.

The rate of vertical transmission of HIV-1 has fallen ... Since zidovudine is the drug with the best track record in reducing vertical transmission, an initial regimen should contain zidovudine ...

The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...

A 33-year-old man presented to our dermatology clinic with a 1-month history of two painless ulcers on his right arm and ...

Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...